Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia - Report - MDSpire
Prognostic Significance of Re-Induction Necessity in Acute Myeloid Leukemia
Overview
This study evaluates the prognostic significance of re-induction based on day-14 residual disease in acute myeloid leukemia (AML) patients. It finds that the need for re-induction is associated with relapse-free and overall survival outcomes.
Background
Acute myeloid leukemia (AML) treatment aims for complete remission, yet residual disease at day 14 can complicate prognosis. This study investigates how residual disease and re-induction influence survival rates in AML patients undergoing intensive chemotherapy.
Data Highlights
Measure
Median
1-Year Rate
2-Year Rate
3-Year Rate
RFS
18 months
63%
42%
35%
OS
76 months
52% (5-year)
-
-
Key Findings
Re-induction was necessary for 27% of patients to achieve CR/CRi.
Median RFS was 14 months for those requiring re-induction versus 22 months for those who did not (p < 0.01).
Age ≥65 years, post-CMN status, and ELN adverse karyotype were independent predictors of relapse.
Median OS was 37 months for patients requiring re-induction compared to 106 months for those who did not (p < 0.01).
Clinical Implications
The findings highlight the implications of re-induction on patient outcomes.
Conclusion
This study evaluates the prognostic relevance of re-induction necessity in AML, suggesting that early assessment of residual disease can inform treatment decisions.
by Abiola Bolarinwa, Muhammad Yousuf, Aref Al-Kali, Hassan B. Alkhateeb, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, Michelle A. Elliott, Mark R. Litzow, William J. Hogan, Mithun V. Shah, Mrinal M. Patnaik, Animesh Pardanani, Dong Chen, Kaaren K. Reichard, Rong He, Naseema Gangat, Ayalew Tefferi, Kebede H. Begna
The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.
Harold Burstein, MD, PhD, and Rachel Freedman, MD, MPH discuss the results of a new study looking at the impact of food access and poverty on patients with metastatic breast cancer. They also discuss the new Dana-Farber food pantry and patient navigators who help coordinate care.
